The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03B | Other drugs for obstructive airway diseases, inhalants | |
| 4 | R03BB | Anticholinergics | |
| 5 | R03BB07 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| RESPIR - Respiratory (Inhalation) (powder) | 55 ug |
| Active Ingredient | Description | |
|---|---|---|
| Umeclidinium |
Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium bromide exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| INCRUSE ELLIPTA Inhalation powder, pre-dispensed | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
